Screener
Indivior Pharmaceuticals, Inc. INDV Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Indivior Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Indivior Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-028850
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Accrued litigation settlement expenses, noncurrent | 41 | 52 |
| Operating lease liabilities, noncurrent | 14 | 22 |
| Other noncurrent liabilities | 21 | 21 |
| Total liabilities | $1,341 | $1,300 |
| Commitments and contingencies (Note 12) | ||
| Stockholders' deficit | ||
| Common stock, par value $0.001 per share (2026) and $0.50 per share (2025). Issued shares: 122 (2026) and 125 (2025) | — | 62 |
| Additional paid-in capital | 165 | 112 |
Item 1. Unaudited Condensed Financial Statements.
FAQ
- What is Indivior Pharmaceuticals, Inc.'s total liabilities?
- Indivior Pharmaceuticals, Inc. (INDV) reported total liabilities of $1.34B in Q1 2026.
- How has Indivior Pharmaceuticals, Inc.'s total liabilities changed year-over-year?
- Indivior Pharmaceuticals, Inc.'s total liabilities decreased by 19.2% year-over-year, from $1.66B to $1.34B.
- What is the long-term trend for Indivior Pharmaceuticals, Inc.'s total liabilities?
- Over 2 years (2023 to 2025), Indivior Pharmaceuticals, Inc.'s total liabilities has grown at a -18.2% compound annual growth rate (CAGR), from $1.94B to $1.3B.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Indivior Pharmaceuticals, Inc.'s total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude